A Phase 3 interventional study of Insulin icodec and Insulin glargine in Diabetes, Type 2, sponsored by Novo Nordisk A/S. Completed at 83 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 — 2 open to participants now, 2 under way, none of them phase 3. insulin icodec · Diabetes Mellitus, Type 2.
Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment, is one of 2 that started in 2024, is one of 9 in phase 3, and was the 25th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →2 of the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Canada, Germany, Italy
Ages 18+
Xi'an International Medical Center Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
insulin icodec: first FDA approval 2026 (AWIQLI FLEXTOUCH), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 412 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 84 across the 27 interventional studies. Of the 25 that completed or were terminated, 12 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 27 have an industry lead sponsor. The 2 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 129th largest by enrollment of the 428 interventional ones that give a count, is one of 26 that started in 2024, is one of 187 in phase 3, and was the 597th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin icodec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07747402Xi'an International Medical Center HospitalInsulin Icodec Initiation Strategies and Day-4 Supplemental Dosing in Type 2 Diabetes | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment participants get is decided by chance. Insulin icodec is the new medicine being tested, while insulin glargine is already approved and can be prescribed by doctors. Participants will get one injection of insulin icodec once a week, or one injection of insulin glargine once a day, depending on the treatment group participants are assigned into. Participants will use a pen with a small needle to inject the medicine under participants skin into participants thigh, upper arm or stomach.The study will last for about 9 months, but participants will only be taking the study medicine for 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Insulin icodec subcutaneously once weekly.
Drug: Insulin icodec · Drug: Insulin glargine
Participants will receive Insulin glargine subcutaneously once daily.
Drug: Insulin icodec · Drug: Insulin glargine
Insulin Icodec will be administered subcutaneously.
Insulin glargine will be administered subcutaneously.
Change in Glycated Haemoglobin (HbA1c)
Change in HbA1c from week 0 to week 26 in percentage point is presented.
Time frame: Week 0, Week 26
Change in Time in Range 3.9-10.0 Millimoles Per Litre (mmol/L) (70-180 Milligrams Per Decilitre (mg/dL))
Change in time in range 3.9-10.0 mmol/L (70-180 mg/dL) from week -4-0 to week 22-26 is presented. Time in range is defined as 100 times the number of recorded measurements in glycaemic range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive, divided by the total number of recorded measurements.
Time frame: week -4-0, week 22-26
Change in DTSQs (Diabetes Treatment Satisfaction Questionnaire Status Version) Total Treatment Satisfaction
Change in DTSQs total treatment satisfaction from week 0 to week 26 is presented. DTSQs measures the satisfaction with diabetes treatment regimens in people with diabetes. The measure consists of 8 items, of which 6 items contribute to 1 global score. Total Treatment Satisfaction score range is 0-36. 6 items scored on a scale of 0 to 6. The higher the score the greater the satisfaction with treatment.
Time frame: week 0 to week 26
Number of Severe Hypoglycaemic Episodes (Level 3)
Number of severe hypoglycaemic episodes (level 3) from baseline (week 0) to week 31 is presented.
Time frame: From baseline (week 0) to week 31
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by Blood Glucose (BG) Meter)
Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) from baseline (week 0) to week 31 is presented.
Time frame: From baseline (week 0) to week 31
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)
Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) from baseline (week 0) to week 31 is presented.
Time frame: From baseline (week 0) to week 31
Time Spent < 3.0 mmol/L (54 mg/dL)
Time spent \< 3.0 mmol/L (54 mg/dL) during week 22 - 26 is presented. Time spent below threshold is defined as 100 times the number of recorded measurements below 3.0 mmol/L (54 mg/dL), divided by the total number of recorded measurements.
Time frame: Week 22-26
Change in Time Spent > 10.0 mmol/L (180 mg/dL)
Change in time spent \> 10.0 mmol/L 180 mg/dL from week -4 - 0 to week 22-26 is presented. Time spent above threshold is defined as 100 times the number of recorded measurements above 10.0 mmol/L (180 mg/dL) divided by the total number of recorded measurements.
Time frame: Week -4-0, Week 22-26
Mean Weekly Insulin Dose
Mean weekly insulin dose from week 24 to week 26 is presented.
Time frame: From week 24 to week 26
Change in Body Weight
Change in body weight from baseline (week 0) to (week 26) is presented.
Time frame: Week 0, Week 26
The trial was conducted at 66 sites in 8 countries.
| Milestone | Insulin Icodec | Insulin Glargine |
|---|---|---|
| Started | 206 | 206 |
| Full analysis set | 206 | 206 |
| Safety analysis set | 206 | 206 |
| Completed | 206 | 203 |
| Not completed | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 3 |
Change in HbA1c from week 0 to week 26 in percentage point is presented.
| Percentage (%) point | Insulin Icodec | Insulin Glargine |
|---|---|---|
| Change in Glycated Haemoglobin (HbA1c) | -0.84 ± 0.83 | -0.58 ± 0.89 |
Change in time in range 3.9-10.0 mmol/L (70-180 mg/dL) from week -4-0 to week 22-26 is presented. Time in range is defined as 100 times the number of recorded measurements in glycaemic range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive, divided by the total number of recorded measurements.
| Percentage (%) of time | Insulin Icodec | Insulin Glargine |
|---|---|---|
| Change in Time in Range 3.9-10.0 Millimoles Per Litre (mmol/L) (70-180 Milligrams Per Decilitre (mg/dL)) | 19.94 ± 20.49 | 11.04 ± 19.43 |
Change in DTSQs total treatment satisfaction from week 0 to week 26 is presented. DTSQs measures the satisfaction with diabetes treatment regimens in people with diabetes. The measure consists of 8 items, of which 6 items contribute to 1 global score. Total Treatment Satisfaction score range is 0-36. 6 items scored on a scale of 0 to 6. The higher the score the greater the satisfaction with treatment.
| Score on a scale | Insulin Icodec | Insulin Glargine |
|---|---|---|
| Change in DTSQs (Diabetes Treatment Satisfaction Questionnaire Status Version) Total Treatment Satisfaction | 3.94 ± 6.96 | 2.20 ± 5.94 |
Number of severe hypoglycaemic episodes (level 3) from baseline (week 0) to week 31 is presented.
| Episodes | Insulin Icodec | Insulin Glargine |
|---|---|---|
| Number of Severe Hypoglycaemic Episodes (Level 3) | 2 | 1 |
Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) from baseline (week 0) to week 31 is presented.
| Episodes | Insulin Icodec | Insulin Glargine |
|---|---|---|
| Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by Blood Glucose (BG) Meter) | 53 | 70 |
Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) from baseline (week 0) to week 31 is presented.
| Episodes | Insulin Icodec | Insulin Glargine |
|---|---|---|
| Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3) | 55 | 71 |
Time spent \< 3.0 mmol/L (54 mg/dL) during week 22 - 26 is presented. Time spent below threshold is defined as 100 times the number of recorded measurements below 3.0 mmol/L (54 mg/dL), divided by the total number of recorded measurements.
| % of time | Insulin Icodec | Insulin Glargine |
|---|---|---|
| Time Spent < 3.0 mmol/L (54 mg/dL) | 0.27 ± 0.48 | 0.23 ± 0.54 |
Change in time spent \> 10.0 mmol/L 180 mg/dL from week -4 - 0 to week 22-26 is presented. Time spent above threshold is defined as 100 times the number of recorded measurements above 10.0 mmol/L (180 mg/dL) divided by the total number of recorded measurements.
| % of time | Insulin Icodec | Insulin Glargine |
|---|---|---|
| Change in Time Spent > 10.0 mmol/L (180 mg/dL) | -20.54 ± 21.10 | -11.19 ± 19.94 |
Mean weekly insulin dose from week 24 to week 26 is presented.
| Units of insulin/week | Insulin Icodec | Insulin Glargine |
|---|---|---|
| Mean Weekly Insulin Dose | 278.45 ± 71.44 | 270.19 ± 62.45 |
Change in body weight from baseline (week 0) to (week 26) is presented.
| Kilogram (kg) | Insulin Icodec | Insulin Glargine |
|---|---|---|
| Change in Body Weight | 2.04 ± 2.87 | 0.55 ± 3.16 |
Collected over From week 1 to week 31. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Icodec | 0/206 (0%) | 16/206 (7.8%) | 42/206 (20.4%) |
| Insulin Glargine | 0/206 (0%) | 12/206 (5.8%) | 30/206 (14.6%) |
| Event | Insulin Icodec | Insulin Glargine |
|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 0/206 | 2/206 |
| PneumoniaInfections and infestations | 2/206 | 2/206 |
| Acquired oesophageal webGastrointestinal disorders | 0/206 | 1/206 |
| Alanine aminotransferase increasedInvestigations | 0/206 | 1/206 |
| Angina unstableCardiac disorders | 1/206 | 0/206 |
| Arthritis bacterialInfections and infestations | 0/206 | 1/206 |
| Aspartate aminotransferase increasedInvestigations | 0/206 | 1/206 |
| Atrial flutterCardiac disorders | 1/206 | 0/206 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/206 | 0/206 |
| Bronchitis bacterialInfections and infestations | 1/206 | 0/206 |
| Event | Insulin Icodec | Insulin Glargine |
|---|---|---|
| NasopharyngitisInfections and infestations | 28/206 | 16/206 |
| Diabetic retinopathyEye disorders | 6/206 | 15/206 |
| DiarrhoeaGastrointestinal disorders | 11/206 | 4/206 |
Full analysis set included all randomised participants.
| Age, Continuous(Years) | Insulin Icodec | Insulin Glargine | Total |
|---|---|---|---|
| Mean | 62.41 ± 9.91 | 62.52 ± 9.65 | 62.47 ± 9.77 |
| Sex: Female, Male(Participants) | Insulin Icodec | Insulin Glargine | Total |
|---|---|---|---|
| Female | 84 | 90 | 174 |
| Male | 122 | 116 | 238 |
| Ethnicity (NIH/OMB)(Participants) | Insulin Icodec | Insulin Glargine | Total |
|---|---|---|---|
| Hispanic or Latino | 26 | 27 | 53 |
| Not Hispanic or Latino | 178 | 175 | 353 |
| Unknown or Not Reported | 2 | 4 | 6 |
| Race/Ethnicity, Customized(Participants) | Insulin Icodec | Insulin Glargine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 69 | 74 | 143 |
| Black or African American | 8 | 8 | 16 |
| White | 127 | 122 | 249 |
| American Indian or Alaska Native, White | 0 | 1 | 1 |
| Not reported | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.
Data sharing details ↗ · novonordisk-trials.com
Ran from Apr 2024 to primary completion in May 2025, 12 months.
Results were first posted in Jul 2026, 1 year 1 month after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 12 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin icodec · Insulin Glargine